COMPASS Pathways, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $23.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ritu Baral has given her Buy rating due to a combination of factors related to COMPASS Pathways’ strategic progress and financial stability. The company is actively engaging with the FDA to discuss preliminary data and potential accelerated approval pathways for its COMP360 therapy in treatment-resistant depression (TRD). Additionally, the submission of a National Priority Voucher program application highlights the company’s proactive approach in advancing its clinical programs.
Moreover, COMPASS Pathways has a solid financial position, with a cash runway extending to 2027, which supports its ongoing research and development activities. The upcoming release of topline data from key studies, including the Phase 3 TRD study, is expected to provide further insights into the efficacy and safety of COMP360. The company’s decision to protect against patient unblinding in trials addresses FDA concerns and demonstrates a commitment to maintaining rigorous trial standards. These strategic and financial considerations underpin Baral’s positive outlook on the stock.